Cormedix Inc (CRMD) 1.77 $CRMD
CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification
PR Newswire - Tue Sep 16, 7:00AM CDT
CorMedix Inc. ("CorMedix"
(NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, announces the amendment and restatement of its outstanding Series C-2, C-3, D and E preferred stock and related warrants, as well as the warrants issued in its March 2014 common stock and warrant financing, to remove anti-dilution, price reset and certain change of control provisions that caused those securities to be classified as derivative liabilities under U.S. generally accepted accounting principles. In addition, the dividend payable on each of the Series D preferred stock and Series E preferred stock was eliminated.
FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
PR Newswire - Thu Aug 14, 3:45PM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the U.S. Food and Drug Administration (FDA) has agreed with the design of our pivotal Phase III protocol for Neutrolin® in Hemodialysis patients, and the company plans to submit the IND for Neutrolin within the next 30 days. The FDA will then have 30 days to respond to the IND. The pivotal Phase 3 randomized controlled trial ("RCT" for Neutrolin is for use in hemodialysis patients with a central venous catheter. The Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe. Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program.
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
CorMedix, Inc. Granted Extension of NYSE-MKT Listing
PR Newswire - Thu Jul 24, 11:30AM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announces receipt of notice on July 18, 2014 from the NYSE MKT LLC (NYSE-MKTS) that the NYSE-MKT has accepted the CorMedix plan to regain compliance with continued listing standards of the NYSE-MKT. As a result, the NYSE-MKT is continuing the Company's listing and has granted the Company an extension until May 31, 2015 to regain compliance with the continued listing standards of the NYSE-MKT. The Company will be subject to periodic review by the NYSE-MKT during the extended plan period.
CorMedix announces planned Neutrolin Pivotal Phase 3 study trial under the guidance of US FDA
M2 - Tue Jun 24, 4:40AM CDT
Pharmaceutical company CorMedix (NYSE MKT:CRMD) said on Monday that it has finalised its planned pivotal Phase 3 randomised controlled trial (RCT) for Neutrolin for use in hemodialysis patients with a central venous catheter with the US Food and Drug Administration (US FDA).
CorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol for FDA
PR Newswire - Mon Jun 23, 3:15PM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the progress of on-going discussions with the U.S. Food and Drug Administration for a planned pivotal Phase 3 randomized controlled trial ("RCT" for Neutrolin® for use in hemodialysis patients with a central venous catheter. CorMedix worked with the FDA to develop the protocol design for the planned trial for a marketing application. Based on FDA input, the planned Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe. Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program.
CorMedix Inc. to Report 2013 Year End Results on March 31, 2014, and Host Conference Call at 9 am on April 1, 2014
PR Newswire - Thu Mar 27, 5:39PM CDT
CorMedix Inc. ("CorMedix" (NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases in both acute and chronic care settings, today announced that it will report 2013 financial results on Monday, March 31, 2014. The Company's Chief Executive Officer, Randy Milby, will be hosting a conference call on Tuesday, April 1, 2014 at 9:00 a.m. ET to discuss the Company's 2013 results.
3 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 26, 5:00AM CDT
Keep your eye on these under-$10 biotech stocks.
i"CorMedix concludes USD7.4m registered direct offering of securities
M2 - Tue Mar 11, 7:19AM CDT
US-based pharmaceutical company CorMedix (NYSE MKT:CRMD) disclosed on Monday the completion of its USD7.4m registered direct offering of common stock and warrant units.
CorMedix Inc. Announces Close of Registered Direct Offering
PR Newswire - Mon Mar 10, 3:05PM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, announced today that it has closed its previously announced registered direct offering of common stock and warrant units for gross proceeds to the Company of $7.4 million.
CorMedix reports USD7.4m in registered direct offering
M2 - Wed Mar 05, 5:19AM CST
US-based pharmaceutical company CorMedix (NYSE MKT:CRMD) said on Tuesday that it has entered into USD7.4m registered direct offering with investors.
CorMedix Inc. Announces Registered Direct Offering
PR Newswire - Tue Mar 04, 8:50PM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, announced today that it entered into agreements with investors for a registered direct offering of 2.96 million units at the price of $2.50 per unit resulting in gross proceeds to the Company of $7.4 million.
It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
at The Street - Tue Jan 21, 6:00AM CST
Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.
CorMedix Expands Neutrolin® Sales with Middle East Distribution Agreements
PR Newswire - Mon Jan 13, 7:30AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced the establishment of letters of intent for the importation, sales, marketing and distribution of the Neutrolin catheter lock solution with two leading Middle East distributors, expanding the Company's sales presence to Oman, Yemen and Saudi Arabia.
CorMedix Awarded European Patent for Neutrolin
PR Newswire - Fri Jan 10, 7:32AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced that the European Patent Office ("EPO" has granted a European patent for a low heparin catheter lock solution for maintaining patency and preventing infection in a hemodialysis catheter (sometimes referred to as "the Prosl patent" . The Company is the exclusive worldwide licensee of European Patent EP 1 814 562 B1, which was granted on January 8, 2014.
CorMedix Inc. to Raise $2,000,000 in Follow On Offering
PR Newswire - Wed Jan 08, 8:16AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced that it has entered into securities purchase agreements with investors pursuant to which it has agreed to sell 200,000 shares of Series C-3 Non-Voting Convertible preferred stock and a warrant to purchase up to 1,000,000 shares of common stock for aggregate gross proceeds of $2,000,000. This is the second tranche of funds contemplated and priced in the company's October 2013 Series C preferred stock financing to bolster the Company's cash position which management now projects to be sufficient to fund operations through the achievement of a break even sales run rate. The net proceeds of the financing will be used for general corporate purposes, including the development and commercialization of Neutrolin®, and working capital and capital expenditures. No underwriter or placement agent was used in this transaction.
CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
PR Newswire - Thu Sep 05, 6:00AM CDT
CorMedix Inc. ("CorMedix" (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces receipt of an official communication issued by the European Patent Office which states that the Examining Division intends to grant a European Patent on the basis of European Application No. 05803391.1, "Antimicrobial Locking Solutions Comprising Taurinamide Derivatives and Biologically Acceptable Salts and Acids, with the addition of Small Concentrations of Heparin" which CorMedix refers to as the "Prosl" patent application. The Prosl patent application was approved on the basis of the claim set filed on July 5, 2013. The Prosl patent application is directed to a novel solution containing Taurolidine, citrate and heparin and its use.
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f2gqgd/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013" report to their offering. 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). Scope - A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure). - A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Eli Lilly and Company Quark Pharmaceuticals, Inc. Novartis AG Kureha Corporation OPKO Health, Inc. Evotec Aktiengesellschaft La Jolla Pharmaceutical Company Alexion Pharmaceuticals, Inc. Acceleron Pharma, Inc. Catabasis Pharmaceuticals, Inc. Reata Pharmaceuticals, Inc. Angion Biomedica Corp. Thrasos, Inc. Concert Pharmaceuticals, Inc. CorMedix, Inc. Bolder Biotechnology, Inc. Vitae Pharmaceuticals, Inc. Stelic Institute & Co. Sorbent Therapeutics, Inc. Vicore Pharma AB Cellmid Ltd InVasc Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/f2...nic_kidney About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CorMedix Reports Second Quarter 2013 Results
PR Newswire - Wed Aug 14, 5:48PM CDT
CorMedix Inc. ("CorMedix" (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces its financial results for the second quarter ended June 30, 2013. With the receipt in July 2013 of the CE Mark for Neutrolin®, CorMedix is now focused on commercializing Neutrolin in the European Union and rest of world. CorMedix estimates the market potential for Neutrolin to be between $300 - 400 million.
CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification
PR Newswire - Tue Sep 16, 7:00AM CDT
CorMedix Inc. ("CorMedix"
(NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, announces the amendment and restatement of its outstanding Series C-2, C-3, D and E preferred stock and related warrants, as well as the warrants issued in its March 2014 common stock and warrant financing, to remove anti-dilution, price reset and certain change of control provisions that caused those securities to be classified as derivative liabilities under U.S. generally accepted accounting principles. In addition, the dividend payable on each of the Series D preferred stock and Series E preferred stock was eliminated. FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
PR Newswire - Thu Aug 14, 3:45PM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the U.S. Food and Drug Administration (FDA) has agreed with the design of our pivotal Phase III protocol for Neutrolin® in Hemodialysis patients, and the company plans to submit the IND for Neutrolin within the next 30 days. The FDA will then have 30 days to respond to the IND. The pivotal Phase 3 randomized controlled trial ("RCT"
for Neutrolin is for use in hemodialysis patients with a central venous catheter. The Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe. Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program. 4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
CorMedix, Inc. Granted Extension of NYSE-MKT Listing
PR Newswire - Thu Jul 24, 11:30AM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announces receipt of notice on July 18, 2014 from the NYSE MKT LLC (NYSE-MKTS) that the NYSE-MKT has accepted the CorMedix plan to regain compliance with continued listing standards of the NYSE-MKT. As a result, the NYSE-MKT is continuing the Company's listing and has granted the Company an extension until May 31, 2015 to regain compliance with the continued listing standards of the NYSE-MKT. The Company will be subject to periodic review by the NYSE-MKT during the extended plan period.
CorMedix announces planned Neutrolin Pivotal Phase 3 study trial under the guidance of US FDA
M2 - Tue Jun 24, 4:40AM CDT
Pharmaceutical company CorMedix (NYSE MKT:CRMD) said on Monday that it has finalised its planned pivotal Phase 3 randomised controlled trial (RCT) for Neutrolin for use in hemodialysis patients with a central venous catheter with the US Food and Drug Administration (US FDA).
CorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol for FDA
PR Newswire - Mon Jun 23, 3:15PM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the progress of on-going discussions with the U.S. Food and Drug Administration for a planned pivotal Phase 3 randomized controlled trial ("RCT"
for Neutrolin® for use in hemodialysis patients with a central venous catheter. CorMedix worked with the FDA to develop the protocol design for the planned trial for a marketing application. Based on FDA input, the planned Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe. Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program. CorMedix Inc. to Report 2013 Year End Results on March 31, 2014, and Host Conference Call at 9 am on April 1, 2014
PR Newswire - Thu Mar 27, 5:39PM CDT
CorMedix Inc. ("CorMedix"
(NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases in both acute and chronic care settings, today announced that it will report 2013 financial results on Monday, March 31, 2014. The Company's Chief Executive Officer, Randy Milby, will be hosting a conference call on Tuesday, April 1, 2014 at 9:00 a.m. ET to discuss the Company's 2013 results. 3 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 26, 5:00AM CDT
Keep your eye on these under-$10 biotech stocks.
i"CorMedix concludes USD7.4m registered direct offering of securities
M2 - Tue Mar 11, 7:19AM CDT
US-based pharmaceutical company CorMedix (NYSE MKT:CRMD) disclosed on Monday the completion of its USD7.4m registered direct offering of common stock and warrant units.
CorMedix Inc. Announces Close of Registered Direct Offering
PR Newswire - Mon Mar 10, 3:05PM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, announced today that it has closed its previously announced registered direct offering of common stock and warrant units for gross proceeds to the Company of $7.4 million.
CorMedix reports USD7.4m in registered direct offering
M2 - Wed Mar 05, 5:19AM CST
US-based pharmaceutical company CorMedix (NYSE MKT:CRMD) said on Tuesday that it has entered into USD7.4m registered direct offering with investors.
CorMedix Inc. Announces Registered Direct Offering
PR Newswire - Tue Mar 04, 8:50PM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, announced today that it entered into agreements with investors for a registered direct offering of 2.96 million units at the price of $2.50 per unit resulting in gross proceeds to the Company of $7.4 million.
It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
at The Street - Tue Jan 21, 6:00AM CST
Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.
CorMedix Expands Neutrolin® Sales with Middle East Distribution Agreements
PR Newswire - Mon Jan 13, 7:30AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced the establishment of letters of intent for the importation, sales, marketing and distribution of the Neutrolin catheter lock solution with two leading Middle East distributors, expanding the Company's sales presence to Oman, Yemen and Saudi Arabia.
CorMedix Awarded European Patent for Neutrolin
PR Newswire - Fri Jan 10, 7:32AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced that the European Patent Office ("EPO"
has granted a European patent for a low heparin catheter lock solution for maintaining patency and preventing infection in a hemodialysis catheter (sometimes referred to as "the Prosl patent" . The Company is the exclusive worldwide licensee of European Patent EP 1 814 562 B1, which was granted on January 8, 2014. CorMedix Inc. to Raise $2,000,000 in Follow On Offering
PR Newswire - Wed Jan 08, 8:16AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced that it has entered into securities purchase agreements with investors pursuant to which it has agreed to sell 200,000 shares of Series C-3 Non-Voting Convertible preferred stock and a warrant to purchase up to 1,000,000 shares of common stock for aggregate gross proceeds of $2,000,000. This is the second tranche of funds contemplated and priced in the company's October 2013 Series C preferred stock financing to bolster the Company's cash position which management now projects to be sufficient to fund operations through the achievement of a break even sales run rate. The net proceeds of the financing will be used for general corporate purposes, including the development and commercialization of Neutrolin®, and working capital and capital expenditures. No underwriter or placement agent was used in this transaction.
CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
PR Newswire - Thu Sep 05, 6:00AM CDT
CorMedix Inc. ("CorMedix"
(NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces receipt of an official communication issued by the European Patent Office which states that the Examining Division intends to grant a European Patent on the basis of European Application No. 05803391.1, "Antimicrobial Locking Solutions Comprising Taurinamide Derivatives and Biologically Acceptable Salts and Acids, with the addition of Small Concentrations of Heparin" which CorMedix refers to as the "Prosl" patent application. The Prosl patent application was approved on the basis of the claim set filed on July 5, 2013. The Prosl patent application is directed to a novel solution containing Taurolidine, citrate and heparin and its use. Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f2gqgd/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013" report to their offering. 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). Scope - A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure). - A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Eli Lilly and Company Quark Pharmaceuticals, Inc. Novartis AG Kureha Corporation OPKO Health, Inc. Evotec Aktiengesellschaft La Jolla Pharmaceutical Company Alexion Pharmaceuticals, Inc. Acceleron Pharma, Inc. Catabasis Pharmaceuticals, Inc. Reata Pharmaceuticals, Inc. Angion Biomedica Corp. Thrasos, Inc. Concert Pharmaceuticals, Inc. CorMedix, Inc. Bolder Biotechnology, Inc. Vitae Pharmaceuticals, Inc. Stelic Institute & Co. Sorbent Therapeutics, Inc. Vicore Pharma AB Cellmid Ltd InVasc Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/f2...nic_kidney About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CorMedix Reports Second Quarter 2013 Results
PR Newswire - Wed Aug 14, 5:48PM CDT
CorMedix Inc. ("CorMedix"
(NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces its financial results for the second quarter ended June 30, 2013. With the receipt in July 2013 of the CE Mark for Neutrolin®, CorMedix is now focused on commercializing Neutrolin in the European Union and rest of world. CorMedix estimates the market potential for Neutrolin to be between $300 - 400 million. 
